

Companion Diagnostics: A Market Review



Companion diagnostics (CDx) are critical medical tools that enhance the efficacy and safety of targeted therapies.

Defined by the FDA, CDx assist healthcare professionals in identifying patients who will benefit most from a therapy, mitigating risks, and monitoring treatment responses.

This paper explores the significance, evolution, and regulatory landscape of CDx, particularly their role in oncology and emerging applications beyond cancer treatment.

Introduction

The landscape of precision medicine has been revolutionised by companion diagnostics. These medical devices ensure that therapies are administered to the right patients at the right time. As

the FDA defines them, CDx serve as essential tools in identifying patient subpopulations most likely to respond positively to treatment, thus improving both safety and efficacy.

The Role of Companion Diagnostics in Medicine

CDx are widely associated with oncology, as evidenced by 146 of the 149 FDA-approved CDx pertain to cancer treatment.

A notable example is Vemurafenib (Zelboraf), a kinase inhibitor for melanoma patients with the V600E mutation, identified via a companion diagnostic test.

However, CDx applications are expanding beyond oncology:

- **Gene Therapy:** The FDA-approved AAV5 Detect CDx immunoassay screens for AAV5 mutations, ensuring appropriate use of BioMarin's gene therapy Val-rox.
- **Chronic Disease Management:** Blood glucose meters used in diabetes and hormone level tests in fertility treatments function similarly to CDx, guiding drug administration without requiring FDA-mandated approval.

Emerging Trends and Market Evolution

The market is evolving to include new areas such as:

- **At-home disease monitoring:** Patients with conditions like sickle cell disease, undergoing



Casgevy gene therapy, require regular monitoring, highlighting the potential for at-home CDx.

- Cell and gene therapies: Immunologic drugs and CAR-T therapies may cause cytokine release syndrome, which necessitates rapid blood testing to tailor antibody treatments effectively.

Challenges and Barriers to Adoption

Despite their advantages, companion diagnostics face several challenges:

- Biomarker Limitations: Some diseases, such as asthma, lack clear biomarkers to guide treatment selection.
- Compliance Issues: Technologies like smart pills for schizophrenia treatment face patient resistance due to concerns about privacy and tracking.

- Regulatory Complexity: Unlike drugs, CDx undergo different regulatory approval processes, often requiring Class II Premarket Applications instead of the simpler 510(k) pathway.
- Economic Viability: Reimbursement challenges can discourage widespread adoption, particularly for costly diagnostic tools.

Companion diagnostics play an essential role in the advancement of precision medicine. While their use has traditionally been centered on oncology, there is growing potential in gene therapies, chronic disease management, and at-home diagnostic solutions.

Overcoming regulatory, compliance, and economic challenges will be crucial in expanding their role in personalised medicine.

Opportunities and Strategic Advantages of Companion Diagnostics

The development and utilization of companion diagnostics present numerous advantages for patients, healthcare professionals, and pharmaceutical companies.

From improving treatment success rates to facilitating efficient regulatory approvals, they are indispensable tools in modern medicine.

Advantages Across Stakeholders

- Patients: CDx contribute to increased treatment success, reduced side effects, and minimised ineffective hospital visits.
- Healthcare Professionals: Diagnostic insights assist in identifying responsive patients,

approaches.

- **Pharmaceutical Companies:**
- **Clinical Trials:** CDx improve the likelihood of meeting endpoints and securing regulatory approvals. Studies indicate that 65% of FDA and EMA drug approvals between 2015 and 2019 involved at least one biomarker consideration.
- **Market Positioning:** Post-approval, CDx help establish first-line treatment status for targeted patient subsets, reinforcing intellectual property (IP) strategies.

Economic and Strategic Considerations

Cost Implications: CDx reduce wasted drug expenditures and hospitalisations by ensuring only suitable patients receive specific treatments.

They impact reimbursement strategies, influencing pricing models in healthcare systems.

Clinical Trial Optimisation: Drug approval rates improve when biomarkers are incorporated.

Precision medicine strategies enhance regulatory compliance and market access.

Future Considerations and Expansion

Gene Therapy: Advances in personalised medicine are driving CDx adoption for gene therapies.

At-home Testing: The shift towards decentralised healthcare demands more accessible diagnostic solutions.

AI and Machine Learning Integration: Predictive analytics will refine biomarker discovery, enhancing diagnostic precision.

The strategic value of companion diagnostics continues to grow, offering advantages in drug development, regulatory navigation, and personalised treatment planning. As technology evolves, CDx will expand into new therapeutic areas, driving innovation and improving patient outcomes.

Future Trends and Regulatory Considerations in Companion Diagnostics

The future of companion diagnostics is being shaped by technological advancements and regulatory considerations. As healthcare moves towards personalised and decentralised care, the development of CDx must adapt to emerging demands and compliance standards.

Key Trends in Companion Diagnostics

Growth of At-Home and Self-Test Diagnostics: Patients increasingly manage treatments independently, reducing hospital visits and healthcare costs.

Closed-Loop Therapeutic Systems: Expanding beyond diabetes management (e.g., the Medtronic Artificial Pancreas), automated drug delivery systems will integrate CDx.

AI and Machine Learning: Predictive models analysing multiple biomarkers and behavioral data will enhance diagnostic accuracy and treatment personalisation.

Regulatory and Compliance Challenges

Approval Delays: Regulatory frameworks often lag behind technological advancements, delaying market entry.

Reimbursement Uncertainty: Limited healthcare coverage discourages innovation and adoption.

Intellectual Property and Competition: IP laws for CDx differ from traditional pharmaceuticals, leading to challenges in market exclusivity.

The future of companion diagnostics is poised for growth, with innovations in AI, decentralised testing, and personalised medicine. Addressing regulatory and reimbursement barriers will be essential for maximising their impact in healthcare.

Written by Alex Vasiev, Head of Biointerface, Springboard

Contact us to find out how we can help
contact@springboard.pro